F9 and hemophilia B: In early AAV clinical trials investigating the delivery of factor IX to the liver of hemophilia B patients, it was discovered that although therapeutic levels of factor IX could be achieved at the highest dose of AAV-factor IX, immune responses against the vector capsid limited prolonged expression of the transgene beyond 8 weeks [4].